CIK 0001655923 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in A1 · fiscal year ends 12/31
| FY2025 | FY2024 | |
|---|---|---|
| Revenue (USD) | 10.2 M | |
| Net income (USD) | -20.7 M | -13.8 M |
| Diluted EPS (USD/shares) | -1.18 | -3.84 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-19 | 4 | 4 | 2026-10-15 |
| 2026-10-02 | 4 | 4 | 2026-10-01 |
| 2026-09-28 | 4 | 4 | 2026-09-24 |
| 2026-09-23 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-09-16 | 4 | 4 | 2026-09-14 |
| 2026-08-24 | 4 | FORM 4 | 2026-08-21 |
| 2026-08-13 | 10-Q | QUARTERLY REPORT | 2026-06-30 |
| 2026-08-04 | 4 | 4 | 2026-07-31 |
| 2026-07-28 | 4 | 4 | 2026-07-24 |
| 2026-07-24 | 4 | 4 | 2026-07-22 |
| 2026-07-24 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-06-29 | 4 | 4 | 2026-06-25 |
| 2026-06-29 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-06-23 | 8-K | CURRENT REPORT items 5.02,5.07,9.01 | 2026-06-16 |
| 2026-06-15 | 4 | 4 | 2026-06-11 |
| 2026-06-11 | 4 | 4 | 2026-06-09 |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-05-29 | 4 | 4 | 2026-05-27 |
| 2026-05-22 | 4 | 4 | 2026-05-20 |
| 2026-05-22 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-19 | 4 | FORM 4 | 2026-05-19 |
| 2026-05-19 | 4 | 4 | 2026-05-15 |
| 2026-05-14 | 10-Q | QUARTERLY REPORT | 2026-03-31 |
| 2026-05-12 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-11 | SCHEDULE 13G/A | SCHEDULE 13G/A |
Forms on file (last 1,000): 4 49, 8-K 26, D 17, SCHEDULE 13G/A 12, CORRESP 12, 3 11, SCHEDULE 13G 10, UPLOAD 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ACOG (0.002 USD), /gw/filings/filings?ticker=ACOG&form=8-K, /gw/filings/facts?ticker=ACOG&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange